Titlebook: Rare Hematological Malignancies; Stephen M. Ansell Book 2008 Springer-Verlag US 2008 cell.leukemia.lymphoma.oncology.plasma

潛移默化

Karen L. Chang,David S. Snyder It should be emphasized though that the volume is not a dictionary but represents a compendium of knowledge...Graduate students, scientists and professionals, from a wide variety of disciplines and others who deal with the nature, processes and use of soil will have access to essential information

oblique

采納

Polycythemia Vera and Other Polycythemia Syndromes,a primary disease of unknown cause, PV, or as a secondary manifestation of other illnesses. In the past, the diagnosis of PV was often an exclusionary diagnosis; now it is made more easily because of the . molecular abnormality (.) found in this disease. Untreated PV leads to thrombohemorrhagic comp

minaret

Palpitation

neutrophils

Chronic Myelomonocytic Leukemia,llowed the FAB recommendation (3) and excluded CMML patients with WBC >12 × 10./L from the risk-oriented International Prognostic Scoring System for MDS (IPSS) (3), limiting its usefulness for assessing the expected outcomes of CMML patients(4, 5). The World Health Organization(WHO)included CMML in

變色龍

銼屑

Lymphomatoid Granulomatosis, lymphoma. Consequently, controversy still surrounds the precise nosologic designation of LG as a reactive, inflammatory versus a neoplastic lymphoid process. Some cases of LG would be well characterized as immunosupression-related or posttransplant lymphoproliferative disorders and reduction of imm

Pert敏捷

Posttransplant Lymphoproliferative Disorders, or aggressive, localized or mulitcentric, associated with symptoms or no symptoms, more characteristically involve extranodal sites, and disease in the allograft organ is more common (4–6). The biology, diagnosis, and management of this heterogeneous group of disorders have nuances that are differe

caldron

Rare T-Cell Lymphomas,us panniculitis- like T-cell lymphoma. Each of these lymphomas comprises less than 5% of all the T-cell lymphomas and fewer than 1% of all non-Hodgkin’s lymphomas, making them truly rare hematologic malignancies. Each section reviews increasingly well-described clinical and pathologic characteristic